Corsino, P., Davis, B., Law, M., Chytil, A., Forrester, E., Nørgaard, P., Teoh, N., and Law, B., 2007, Tumors initiated by constitutive Cdk2 activation exhibit TGFß resistance and acquire paracrine mitogenic stimulation during progression, Cancer Res., 67, 3135-3144

Law, M., Forrester, E., Chytil, A., Green, G., Davis, B., Rowe, T., and Law, B., 2006, Rapamycin disrupts Cyclin/Cdk/p21/PCNA complexes and Cyclin D1 reverses rapamycin action by stabilizing these complexes, Cancer Res., 66, 1070-1080

Law, B., 2005, Rapamycin: An anti-cancer immunosuppressant? Critical Reviews in Hematology/Oncology, 56, 47-60

Chytil, C., Waltner-Law, M., West, R., Aakre, M., and Law, B., 2004, Construction of a Cyclin D1-Cdk2 fusion protein to model the biological functions of Cyclin D1/Cdk2 Complexes, J. Biol. Chem., 279, 47688-47698.

Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells.
Mol Cell Biol. 2002 Dec;22(23):8184-98

Brown KA, Roberts RL, Arteaga CL, Law BK
Breast Cancer Res. 2004;6(2):R130-R139. Epub 2004 Feb 04.
Transforming growth factor-beta induces Cdk2 relocalization to the cytoplasm coincident with dephosphorylation of retinoblastoma tumor suppressor protein.

Law Lab

Left to Right: Nicole Parker, Mary Law, Brian Law, Brad Davis & Patrick Corsino
Return to top